Choline therapy in Huntington chorea.

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Neurology

Background:

• Huntington chorea is a progressive neurodegenerative disorder characterized by involuntary movements (chorea).
• Acetylcholine, a neurotransmitter, plays a role in motor control, and its levels may be affected in Huntington chorea.
• Choline is a precursor to acetylcholine, suggesting a potential therapeutic target.

Purpose of the Study:

• To investigate the effect of oral choline chloride administration on plasma choline concentrations in patients with Huntington chorea.
• To assess whether elevated plasma choline levels correlate with changes in involuntary movements in Huntington chorea patients.

Main Methods:

• Five patients diagnosed with Huntington chorea received oral choline chloride at doses ranging from 3 to 15 grams per day.
• Plasma concentrations of free choline were measured to determine the dose-dependent effect of supplementation.
• Clinical observation was used to evaluate changes in involuntary movements.

Main Results:

• Oral choline chloride administration resulted in a sustained, dose-dependent increase in plasma free choline concentrations.
• The achieved plasma choline levels (25-30 mumol/L) were comparable to those known to elevate brain acetylcholine in rodent models.
• No conclusive or significant alteration in the involuntary movements characteristic of Huntington chorea was observed during the treatment period.

Conclusions:

• Choline chloride supplementation effectively increases plasma choline levels in Huntington chorea patients.
• Despite achieving pharmacologically relevant plasma choline concentrations, the treatment did not demonstrate a clear therapeutic benefit for choreiform movements.
• Further research may be needed to explore alternative choline delivery methods or dosages, or other therapeutic strategies for Huntington chorea.